BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

...2016 and $18.8 million in a placing in 2017; (E) Nightstar Therapeutics plc (NASDAQ:NITE), formerly NightstaRx Ltd....
BioCentury | Jul 27, 2018
Product R&D

Syncona’s sister act

...antagonist RPE65 - Retinal pigment epithelium-specific protein 65kDa Karen Tkach Tuzman, Associate Editor Freeline Therapeutics Ltd. Gyroscope Therapeutics Ltd. NightstaRx Ltd. Orbit...
BioCentury | May 18, 2018
Finance

China comes to Europe

...2016 and $18.8 million in a placing last year; (E) Nightstar Therapeutics plc (NASDAQ:NITE), formerly NightstaRx Ltd....
BioCentury | Sep 8, 2017
Financial News

Nightstar, Deciphera, NuCana propose NASDAQ IPOs

...Ophthalmic gene therapy company Nightstar Therapeutics Ltd. (London, U.K.) (formerly NightstaRx Ltd.) filed to raise up to...
BioCentury | Sep 1, 2017
Financial News

Nightstar, Deciphera, NuCana propose NASDAQ IPOs

...Ophthalmic gene therapy company Nightstar Therapeutics Ltd. (London, U.K.) (formerly NightstaRx Ltd.) filed to raise up to...
...is also in Phase III testing as first-line treatment of pancreatic cancer. Elizabeth S. Eaton AAV-XLRPGR AAV2-REP1 Acelarin DCC-2618 Nightstar Therapeutics Ltd. NightstaRx Ltd. NuCana...
BioCentury | Apr 6, 2017
Company News

Management tracks

...CFO, effective May 1. She was CFO at Stadium Group plc (LSE:SDM). Gene therapy company NightstaRx Ltd....
BioCentury | Mar 23, 2017
Clinical News

AAV-XLRPGR: Ph I/II started

...Phase I/II trial to evaluate single subretinal injections of AAV-XLRPGR in about 24 male patients. NightstaRx Ltd....
...RPGR) gene Indication Treat X-linked retinitis pigmentosa Endpoint: Safety Status: Phase I/II started Milestone: NA Julian Zhu AAV-XLRPGR NightstaRx Ltd. Retinitis...
BioCentury | Sep 13, 2016
Company News

Management tracks

...Gene therapy company NightstaRx Ltd. (London, U.K.) named Gregory Robinson CSO. He was CSO at Agilis Biotherapeutics...
BioCentury | May 19, 2016
Finance

Found in translation

...hematology; pulmonary Abingworth Management; Celgene Corp. (NASDAQ:CELG); New Enterprise Associates (NEA); SR One; Versant Ventures NightstaRx Ltd....
BioCentury | May 16, 2016
Finance

Global ambitions

...has disclosed investments in seven European companies: Adaptimmune Therapeutics plc , CRISPR Therapeutics AG , NightstaRx Ltd....
...In NightstaRx case, a U.S. investor pushed the company to think bigger. According to Mott, NightstaRx...
...with this platform?" NEA led a $35 million series B round in November. In parallel, NightstaRx...
Items per page:
1 - 10 of 27
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

...2016 and $18.8 million in a placing in 2017; (E) Nightstar Therapeutics plc (NASDAQ:NITE), formerly NightstaRx Ltd....
BioCentury | Jul 27, 2018
Product R&D

Syncona’s sister act

...antagonist RPE65 - Retinal pigment epithelium-specific protein 65kDa Karen Tkach Tuzman, Associate Editor Freeline Therapeutics Ltd. Gyroscope Therapeutics Ltd. NightstaRx Ltd. Orbit...
BioCentury | May 18, 2018
Finance

China comes to Europe

...2016 and $18.8 million in a placing last year; (E) Nightstar Therapeutics plc (NASDAQ:NITE), formerly NightstaRx Ltd....
BioCentury | Sep 8, 2017
Financial News

Nightstar, Deciphera, NuCana propose NASDAQ IPOs

...Ophthalmic gene therapy company Nightstar Therapeutics Ltd. (London, U.K.) (formerly NightstaRx Ltd.) filed to raise up to...
BioCentury | Sep 1, 2017
Financial News

Nightstar, Deciphera, NuCana propose NASDAQ IPOs

...Ophthalmic gene therapy company Nightstar Therapeutics Ltd. (London, U.K.) (formerly NightstaRx Ltd.) filed to raise up to...
...is also in Phase III testing as first-line treatment of pancreatic cancer. Elizabeth S. Eaton AAV-XLRPGR AAV2-REP1 Acelarin DCC-2618 Nightstar Therapeutics Ltd. NightstaRx Ltd. NuCana...
BioCentury | Apr 6, 2017
Company News

Management tracks

...CFO, effective May 1. She was CFO at Stadium Group plc (LSE:SDM). Gene therapy company NightstaRx Ltd....
BioCentury | Mar 23, 2017
Clinical News

AAV-XLRPGR: Ph I/II started

...Phase I/II trial to evaluate single subretinal injections of AAV-XLRPGR in about 24 male patients. NightstaRx Ltd....
...RPGR) gene Indication Treat X-linked retinitis pigmentosa Endpoint: Safety Status: Phase I/II started Milestone: NA Julian Zhu AAV-XLRPGR NightstaRx Ltd. Retinitis...
BioCentury | Sep 13, 2016
Company News

Management tracks

...Gene therapy company NightstaRx Ltd. (London, U.K.) named Gregory Robinson CSO. He was CSO at Agilis Biotherapeutics...
BioCentury | May 19, 2016
Finance

Found in translation

...hematology; pulmonary Abingworth Management; Celgene Corp. (NASDAQ:CELG); New Enterprise Associates (NEA); SR One; Versant Ventures NightstaRx Ltd....
BioCentury | May 16, 2016
Finance

Global ambitions

...has disclosed investments in seven European companies: Adaptimmune Therapeutics plc , CRISPR Therapeutics AG , NightstaRx Ltd....
...In NightstaRx case, a U.S. investor pushed the company to think bigger. According to Mott, NightstaRx...
...with this platform?" NEA led a $35 million series B round in November. In parallel, NightstaRx...
Items per page:
1 - 10 of 27